- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02803593
To Enhance Breast Cancer Survivorship of Asian Americans (TICAA)
28 giugno 2022 aggiornato da: Eun-Ok Im, Emory University
The purpose of this randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.
Panoramica dello studio
Stato
Completato
Condizioni
Descrizione dettagliata
Despite few studies on Asian American breast cancer survivors, it is well known that these women shoulder unnecessary burden of breast cancer because they rarely complain about symptoms or pain, delay seeking help, and rarely ask or get support due to their cultural values and beliefs and language barriers.
This demonstrates a definite need for support in this specific population.
However, survivorship programs that are increasingly instituted at cancer centers have serious impediments to providing information and coaching/support because of the lack of staff time and insurance reimbursement.
Furthermore, the pressure of fast-paced clinical patient-provider interactions leaves little time for health care providers to provide up-to-date information and coaching or support for these women based on their cultural attitudes.
All these circumstances necessitate an innovative and creative delivery method of information and coaching/support.
A technology-based approach using computers and mobile devices (smart phones and tablets) promises to meet this necessity with high flexibility and accessibility, and minimizes the cost of the intervention in busy and costly health care settings.
Also, a technology-based intervention that does not involve face-to-face interactions could work better for many women from cultures where breast cancer is still a stigmatizing experience.
Therefore, based on preliminary studies, the research team has developed and pilot-tested a theory-driven technology-based information and coaching/support program that is culturally tailored to Asian American breast cancer survivors using multiple features.
The purpose of the proposed randomized intervention study is to test the efficacy of the technology-based information and coaching/support program for Asian American breast cancer survivors (TICAA) in enhancing the women's breast cancer survivorship experience.
The specific aims are to: a) determine whether the intervention group will show significantly greater improvements than the control group in primary outcomes (needs for help, physical and psychological symptoms, and quality of life) from baseline (pre-test) to Time Points 1 (post 1-month) and 2 (post 3-months); b) identify theory-based variables (attitudes, self-efficacy, perceived barriers, and social influences related to breast cancer survivorship) that mediate the intervention effects of the TICAA on the primary outcomes at the three time points (pre-test, post 1-month and post 3-months); and c) determine whether the effects of the TICAA on the primary outcomes are moderated by background characteristics and disease factors.
The proposed study will be guided by the Bandura's Theory of Behavioral Change.
This study adopts a randomized repeated measures pretest/posttest control group design in 330 Asian American breast cancer survivors.
The long-term goals are to: (a) implement the program into various health care settings; (b) determine if the TICAA will lead to long-term improved health outcomes; and (c) fundamentally enhance the methodology/paradigm of culturally tailored technology-based interventions for ethnic minority groups of breast cancer survivors.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
199
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University Hospital
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke University, School of Nursing
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
21 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Femmina
Descrizione
Inclusion Criteria:
- Self-reported Asian American women aged 21 years and older who identify their sub-ethnicity as Chinese, Korean, or Japanese
- Have had a breast cancer diagnosis
- Can read and write English, Mandarin Chinese, Korean or Japanese
- Have access to the Internet through computers or mobile devices (smart phones and tablets)
Exclusion Criteria:
- Those under 21 years old are excluded because their cancer experience would be different from adults
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Control
Asian American breast cancer survivors who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS).
Participants are asked to use the online ACS resources for 3 months.
|
The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
|
Sperimentale: TICAA Intervention
Asian American breast cancer survivors who use the TICAA intervention and the information by the ACS.
The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors.
Participants are asked to use the TICAA program for 3 months.
|
The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources.
The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers.
The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship.
The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Support Care Needs Survey (SCNS) Score
Lasso di tempo: Baseline, Month 1, Month 3
|
The SCNS uses 57 items to measure how much help the respondent needs.
Responses are given on a scale from 1 to 5 where 1 = no help is needed and 5 = high need for help.
Total scores range from 57 to 285 and higher scores indicate greater need for help.
|
Baseline, Month 1, Month 3
|
Memorial Symptom Assessment Scale-Short Form (MSAS-SF) Score
Lasso di tempo: Baseline, Month 1, Month 3
|
Physical and psychological symptoms are assessed using the Memorial Symptom Assessment Scale-Short Form (MSAS-SF).
The MSAS-SF asks if the respondent has experienced any of 32 specific symptoms during the past week, with the opportunity for the participant to enter additional symptoms.
The degree of distress experienced by 28 of the symptoms is measured on a scale from 0 (not at all) to 4 (very much).
The total score is the average of the responses to the distress scale items and and ranges from 0 to 4 with higher values indicating greater distress experienced from symptoms.
|
Baseline, Month 1, Month 3
|
Functional Assessment of Cancer Therapy Scale-Breast Cancer (FACT-B) Score
Lasso di tempo: Baseline, Month 1, Month 3
|
Quality of life is assessed using the FACT-B.
The FACT-B includes 41 items which are responded to on a scale from 0 to 4, where 0 = not at all and 4 = very much.
The total score ranges from 0 to 164 and higher scores indicate better quality of life.
|
Baseline, Month 1, Month 3
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Attitudes
Lasso di tempo: Baseline, Month 1, Month 3
|
Attitudes related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Attitudes section of this questionnaire includes 6 items scaled from -3 to 3, where -3 is the most negative score and 3 is the most positive score.
There are also 7 qualitative questions.
The total score for the scaled items ranges from -18 to 18 and higher scores indicate a better attitude towards breast cancer survivorship.
|
Baseline, Month 1, Month 3
|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Perceived Barriers
Lasso di tempo: Baseline, Month 1, Month 3
|
Perceived barriers related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Perceived Barriers section of this questionnaire includes 16 items where responses are given on a 4-point scale where 1 = never and 4 = always.
Total scores range from 16 to 64 and higher scores indicate greater perceived barriers related to breast cancer survivorship.
|
Baseline, Month 1, Month 3
|
Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS) Score for Social Influences
Lasso di tempo: Baseline, Month 1, Month 3
|
Social influences related to breast cancer survivorship are measured using the Questions on Attitudes, Self-Efficacy, Perceived Barriers, and Social Influences (QASPS).
The Social Influences section of this questionnaire includes 3 items where responses are given on a 7-point scale where 1 = disapproval from social support and 7 = approval from social support.
Total scores range from 3 to 21 and higher scores indicate greater positive support from social influences.
|
Baseline, Month 1, Month 3
|
Cancer Behavior Inventory-Brief Version (CBI-B) Score
Lasso di tempo: Baseline, Month 1, Month 3
|
Self-efficacy related to breast cancer survivorship is measured using the Cancer Behavior Inventory-Brief Version (CBI-B).
The CBI-B has 12 items assessing the degree of confidence respondents have with certain coping behaviors on a scale from 1 (not at all confident) to 9 (totally confident).
Total scores range from 12 to 108 where higher scores indicate greater self-efficacy concerning cancer behaviors.
|
Baseline, Month 1, Month 3
|
Personal Resource Questionnaire (PRQ-2000) Score
Lasso di tempo: Baseline, Month 1, Month 3
|
The Personal Resource Questionnaire (PRQ-2000) is a 15-item survey asking how much participants agree or disagree with statements related to social resources on a scale from 1 (strongly disagree) to 7 (strongly agree).
Total scores range from 15 to 105 and higher scores indicate greater social resources.
|
Baseline, Month 1, Month 3
|
Perceived Isolation Scale (PIS) Score
Lasso di tempo: Baseline, Month 1, Month 3
|
The Perceived Isolation Scale (PIS) includes 9 items asking questions about how social connectedness.
Responses are rated on a 3-point scale where 1 = hardly ever, 2 = some of the time, and 3 = often.
The total score is the average of the responses to the PIS items and ranges from 1 to 3 with lower scores indicating greater social connectedness.
|
Baseline, Month 1, Month 3
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Eun-Ok Im, PhD, MPH, Emory University
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
1 giugno 2016
Completamento primario (Effettivo)
9 giugno 2021
Completamento dello studio (Effettivo)
9 giugno 2021
Date di iscrizione allo studio
Primo inviato
14 giugno 2016
Primo inviato che soddisfa i criteri di controllo qualità
14 giugno 2016
Primo Inserito (Stima)
17 giugno 2016
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
29 giugno 2022
Ultimo aggiornamento inviato che soddisfa i criteri QC
28 giugno 2022
Ultimo verificato
1 giugno 2022
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRB00117270
- R01CA203719-01 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
No
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro al seno
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University e altri collaboratoriCompletatoLa guida all'applicazione clinica di Conebeam Breast CTCina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
Prove cliniche su American Cancer Society information on breast cancer
-
University Hospital, BordeauxSRIOP 2016, SIRIC BRIOCompletato
-
Medical University of GrazSconosciutoQualità della vitaAustria, Croazia, Francia, Germania, Italia, Olanda, Polonia, Spagna
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)CompletatoCancro al seno | Cancro colorettale | Cancro alla prostata | Cancro toracicoStati Uniti
-
Memorial Sloan Kettering Cancer CenterAstellas Pharma Inc; Medivation, Inc.Attivo, non reclutanteCancro al seno | Cancro al seno triplo negativo | Fase inizialeStati Uniti
-
TaiHao Medical Inc.Attivo, non reclutanteCancro al seno | Malattie del senoTaiwan
-
CairnSurgical, Inc.SospesoFemmina di cancro al senoStati Uniti, Canada, Regno Unito